Gut and skin: what the axis between belly and face actually holds up
The connection is plausible, in one place even surprisingly well documented, and in many others thinner than the internet tells it. This text names the sample sizes, the German guideline and the studies that contradict one another.
All articles from the gut cluster
Hardly any topic is asserted so often and documented so rarely as the connection between gut and skin. There is exactly one genuinely strong finding in this field, and it even appears in a German guideline. Everything beside it is thinner than it is advertised to be. Both belong in the same text.
You stand in the bathroom in the morning and look at your face. Red again. Those spots again that were not there last night.
The creams are on the shelf, three opened tubes of them. You changed the cleansing gel, then the water, then the pillow. At some point you type into your phone what might be going on in your belly.
And you land in a world that tells you: your skin is the mirror of your gut. With cleanse packages running over several months, with testimonials and with before and after pictures.
Many people know this pattern. And I understand why it pulls. It explains something that feels unexplained, and it gives you something to do.
I am writing this article because I take both seriously. The connection exists, in one place even with numbers that impress me. And at the same time the research base is far narrower than every second consumer page claims. I will show you both, and with the sample sizes.
What awaits you here
- Why gut and skin might be connected at all
- Rosacea and small intestinal bacterial overgrowth, the strongest number in the field
- What the German S2k guideline actually writes about it
- Demodex mites, Helicobacter and the known triggers
- Why two microbiome studies in rosacea contradict each other
- Blemished skin: what is gut and what is metabolism
- Atopic dermatitis: prevention with an effect, treatment without one
- Psoriasis and inflammatory bowel disease
- An overview of how well each skin finding is documented
- Why gut cleanse programmes for the complexion often promise too much
Signs that belong in a medical work-up before anything else happens
This article touches two specialist fields. That is why there are two lists here.
Red flags at the gut
- Blood in the stool or black, tarry stool
- Unintended weight loss
- Fever without a recognisable explanation
- Night time complaints that wake you up
- Vomiting or difficulty swallowing
- A new, persistent change in bowel habit from about 45 to 50 years of age
- Anaemia, meaning a confirmed low blood count
- Bowel cancer or inflammatory bowel disease in the family
Red flags at the skin and the eyes
- A skin lesion that changes shape, colour or size, does not settle or bleeds
- A redness with swelling, warmth and pain that spreads rapidly
- Burning, a foreign body sensation or light sensitivity of the eyes in rosacea
- A persistent redness across the cheeks and the bridge of the nose together with joint pain, exhaustion, hair loss or light sensitivity. That can be harmless, but it can also point to an autoimmune disease such as lupus erythematosus, and that belongs in a medical examination before anything else happens.
- A suddenly shooting sensation of heat with redness that comes together with diarrhoea, a racing heart, breathlessness or circulatory weakness. That belongs in a work-up and should not be filed away as rosacea. With breathlessness, circulatory weakness or rapid deterioration this is an emergency, and then the emergency number 112 applies, not an appointment at a practice.
These signs belong in a medical work-up and are not for self treatment. No gut measure, no cleanse and no supplement replaces a recommended work-up. Eye involvement in rosacea belongs in the hands of an ophthalmologist, because untreated it can affect the cornea.
Why belly and face have anything to do with each other at all
Start with a simple question. What do your gut lining and your facial skin have in common?
Both are boundary surfaces. Both separate your inside from a world full of bacteria. Both have to be tight and permeable at the same time, ready to defend and tolerant. And both arise in the embryo from tissue that takes on exactly this double task.
The skin is the smaller surface of the two. Your gut lining, spread out, measures a multiple of it, and the largest part of your immune system sits along it. When the alarm runs constantly down there, messenger substances travel through the whole body. These messengers know no boundaries between medical specialties.
That is the basic idea of the gut-skin axis. It is not new and it is not esoteric. It is old.
Whitney Bowe and Alan Logan dug out a consideration in 2011 that the American dermatologists John Stokes and Donald Pillsbury had already formulated in 1930: that emotional state, gut flora and the complexion might hang together.
Stokes and Pillsbury suspected that mental tension changes the gut flora and that inflammation arises from this, which is later seen on the skin. Bowe and Logan connected this consideration with modern microbiome research.
For you that means: the idea is almost a hundred years old. It was pure speculation for a long time, it is a research field today, and it is still not a treatment concept.
Bowe WP, Logan AC. Gut Pathogens. 2011;3(1):1. PMID: 21281494 · DOI: 10.1186/1757-4749-3-1 [Mechanism Review]Two mechanisms that get quoted everywhere
Whenever you read about the gut-skin axis somewhere, almost always the same two routes turn up. Both are well studied. Both come from mouse experiments. That matters, and it is rarely mentioned.
Yukihiro Furusawa and a Japanese team investigated in mice what short chain fatty acids do in the large intestine. These fatty acids arise when bacteria ferment fibre.
The more of them there was in the gut content, the more regulatory T cells were found in the gut wall. Butyrate promoted their maturation, and in a colitis model the inflammation turned out milder. Mechanistically this ran through stronger histone acetylation at the Foxp3 gene locus.
For you that means: fibre feeds bacteria, bacteria form butyrate, butyrate promotes braking immune cells. But all of this happened in mice, in the large intestine, without any skin model.
Furusawa Y, Obata Y, Fukuda S et al. Nature. 2013;504(7480):446-450. PMID: 24226770 · DOI: 10.1038/nature12721 [In vivo, mouse]Teresa Zelante and colleagues looked in mice at what happens when gut bacteria metabolise the amino acid tryptophan instead of sugar.
Adaptable lactobacilli multiplied and formed indole-3-aldehyde. This substance docks onto the aryl hydrocarbon receptor, that promoted the formation of interleukin-22, and mucosal defence became more balanced.
For you that means: the same receptor also sits in the skin and is addressed there with medication. The chain from a gut bacterium to your complexion has not been measured through in humans, though.
Zelante T, Iannitti RG, Cunha C et al. Immunity. 2013;39(2):372-385. PMID: 23973224 · DOI: 10.1016/j.immuni.2013.08.003 [In vivo, mouse]The chain everyone means when they say gut-skin axis
- Fibre reaches the large intestine and is fermented by bacteria.
- Short chain fatty acids arise in the process, above all butyrate.
- Butyrate supplies the mucosal cells and promotes regulatory T cells.
- Less alarm at the gut wall could mean fewer messenger substances in the blood.
- Fewer messengers in the blood might lower the inflammatory readiness of the skin.
Steps 1 to 3 are well documented in animal studies. Steps 4 and 5 are considerations. It is exactly at this seam that the text tears open on most consumer pages, because there all five steps sound equally certain.
Then there is the barrier itself. A more permeable gut wall could let more fragments of bacteria into the blood, and the immune system reacts to that. How robust this model is and what zonulin actually says is covered in detail in Leaky gut, gut permeability and zonulin. Here one sentence is enough: the barrier is a plausible candidate, not a proven link.
Plausibility is not proof. It is a good question.
A mechanism that works in animal studies tells you where to look. It does not tell you that something will be found there. Between a coherent story and a documented effect lies half of medicine.
And now you know why I sort the rest of this article by sample sizes and not by stories.
Rosacea, the most striking finding in the whole field
If the gut-skin axis has a hard number anywhere, it is here.
Rosacea is the skin condition with the persistent facial redness, the widened small vessels and, in one form, the inflammatory papules and pustules. It comes in flares. It reacts to heat, alcohol, stress and sun. A suddenly shooting sensation of heat with redness that comes together with diarrhoea or a racing heart does, however, belong in a work-up and should not be filed away as rosacea, because rarer causes can sit behind it. And in many people it goes along with abdominal complaints that nobody connects with the face.
In 2008 a group in Genoa looked into whether that is more than coincidence.
Alfredo Parodi and colleagues examined 113 consecutive people with rosacea and 60 healthy controls matched for age and sex with lactulose and glucose breath tests. Those who tested positive were randomised to rifaximin or placebo.
Small intestinal bacterial overgrowth was found in 52 of 113 compared with 3 of 60 controls, that is 46 against 5 percent, p less than 0.001. After successful eradication the skin lesions had completely regressed in 20 of 28 and were clearly improved in 6 of 28. Under placebo 18 of 20 stayed unchanged, 2 got worse, p less than 0.001. The effect lasted at least nine months.
For you that means: this is the most impressive single finding in this research field, and it comes from a randomised design, not from a survey.
Parodi A, Paolino S, Greco A et al. Clin Gastroenterol Hepatol. 2008;6(7):759-764. PMID: 18456568 · DOI: 10.1016/j.cgh.2008.02.054 [RCT, n=113]Now comes the part that almost nobody quotes along with it, although it is the most important one.
The group also treated 16 people with rosacea whose breath test was negative with the same antibiotic. In 13 of 16 nothing changed on the skin.
Why does that matter so much? Because antibiotics have been used in rosacea for decades, including for their anti inflammatory action on the skin itself. If the rifaximin had simply been a general anti inflammatory, it would have had to change something in the test negative group too. It did not. That speaks for the effect hanging on the finding in the gut.
The same working group looked again years later, this time over a longer period.
Arianna Agnoletti and colleagues examined 60 people with rosacea and 40 controls for three things at once: Demodex mites by surface biopsy, Helicobacter by breath test and small intestinal bacterial overgrowth by breath test. Then they treated in a fixed order and examined again after three years.
Of 88 people with a complete course, 47.7 percent were Demodex positive, 25.0 percent had an overgrowth and 21.6 percent had Helicobacter. The overgrowth clearly predominated in the form with papules and pustules, Helicobacter in the redness dominant form. After six months 61 percent were in remission, and after three years most of them stayed stable.
For you that means: the assignment is clinically interesting. If your rosacea is the inflammatory form with pustules, the question about the small intestine is more obvious than with pure redness. A control arm was missing, though, so nobody knows what would have happened without treatment.
Agnoletti AF, De Col E, Parodi A et al. G Ital Dermatol Venereol. 2017;152(5):418-423. PMID: 26889725 · DOI: 10.23736/S0392-0488.16.05315-3 [Cohort, n=100]What the German guideline writes about it
Here it gets interesting, because on this question the German S2k guideline on rosacea is not the opponent of the gut hypothesis. It is its best ally, and a very precise one.
It counts small intestinal bacterial overgrowth explicitly among the trigger factors, alongside Demodex mites, heat, cold, water vapour, spicy food, UV radiation, exercise, alcohol and cosmetics. It gives a number: in rosacea an overgrowth is present considerably more often, 46 to 51 percent compared with 5 to 23 percent. And it writes that the evidence is thickening for a dysregulation of the microbiota of the digestive tract as a trigger factor in a subgroup.
And then comes the sentence that carries this whole article.
Large randomised multicentre studies validating these observations are still missing.
S2k guideline rosacea, AWMF register no. 013-065, as of 28 January 2022Under research needs the same guideline lists, word for word, the clarification of a possible association between the microbiome of the gut and rosacea. That is not a rejection. That is an open question which a professional society considers important enough to write into its research agenda.
I find this stance exemplary, and I also understand it. An unblinded study from a single centre is not enough to recommend antibiotic therapy outside its licence. That is not stubbornness, that is the usual threshold of proof.
What rifaximin is and what that means for you
- How it behaves
- Rifaximin is a rifamycin derivative that is barely absorbed into the blood. Its action therefore unfolds within the gut space itself.
- What it is licensed for in Germany
- Since 2008 for the treatment of travellers diarrhoea. Its use in rosacea is therefore a use outside the licence.
- How you would get hold of it
- Rifaximin is a prescription only medicine in Germany. You obtain it only on prescription, after a medical examination. A use outside the licence also means that the health insurer usually does not pay and that the duty of medical information is greater than usual.
- What can speak against it
- Like every antibiotic, rifaximin can cause side effects, among them abdominal pain, bloating, nausea and headache. It must not be given in hypersensitivity to rifamycins and in intestinal obstruction. Every course of antibiotics can favour a diarrhoeal illness caused by Clostridioides difficile, and it can promote resistance. In pregnancy, during breastfeeding and in children, separate rules apply. That is one of the reasons why this decision is taken medically and not at the kitchen table. I deliberately give no dosages here.
- What follows from that
- Such a therapy belongs in medical hands, with information about the licence status and with a finding established beforehand. It is nothing you obtain for yourself, and nothing that can sensibly be justified without a positive breath test.
- What the guideline adds
- At the time of the guideline a randomised phase II study was running with a delayed release rifaximin preparation in papulopustular rosacea with a positive breath test. So the field is moving.
How a breath test works, where its weaknesses lie and which other treatment routes exist is described in SIBO, bacterial overgrowth of the small intestine. Why a treated overgrowth comes back so often is explained in Why SIBO comes back.
The counter evidence belongs in the same section
If I stopped here, you would have read a very convincing article. And an incomplete one.
The largest body of data in the field finds nothing exactly here
Alexander Egeberg and colleagues analysed the Danish registers: 49,475 people with rosacea against 4,312,213 controls from the general population, with Cox regression for newly occurring digestive diagnoses.
Significantly raised were coeliac disease with a hazard ratio of 1.46, Crohn disease with 1.45, ulcerative colitis with 1.19 and irritable bowel syndrome with 1.34. Not significant were Helicobacter with 1.04 and small intestinal bacterial overgrowth with 0.71, with a confidence interval from 0.18 to 1.86.
What does that mean? The honest reading is not that the association has been refuted. It is a technical one: small intestinal bacterial overgrowth is hardly ever coded in registers, because it is rarely diagnosed formally. The extremely wide confidence interval shows how few cases stand behind it. This study cannot see the association. That is something other than refuting it.
Egeberg A, Weinstock LB, Thyssen EP et al. Br J Dermatol. 2017;176(1):100-106. PMID: 27501017 · DOI: 10.1111/bjd.14930 [Cohort, n=4,361,688]A team around Jessie Nelson at a US university clinic examined 27 people with rosacea and excluded very strictly: no known digestive disease, no abdominal surgery, no autoimmune disease, defined washout periods for antibiotics, cortisone and stomach acting medication.
An overgrowth was found in 33.3 percent, that is 9 people, and thus significantly more often than in the population estimate. Helicobacter was found in 14.8 percent and thus significantly less often than in the general population. And the abdominal complaints predicted nothing.
For you that means: the signal for the small intestine persists even under strict control. But the belly sometimes stays silent. You can have a positive finding without feeling complaints, and the other way around.
Nelson JM, Rizzo JM, Greene RK et al. Cureus. 2024;16(10):e72363. PMID: 39583431 · DOI: 10.7759/cureus.72363 [Cohort, n=27]The question is not whether rosacea comes from the gut. The question is whether there is a gut finding in you.
That is a completely different sentence. The first claims a cause for everyone. The second leads to an examination in a single person. Only the second is covered by the data.
And now you know why I look closely in papulopustular rosacea with concurrent abdominal complaints, and why with pure redness and no abdominal symptoms at all I do not, at least not at first.
What else plays a part in rosacea, and why the gut does not explain everything
There is one finding in rosacea that is numerically far stronger than anything from the abdomen. It is rarely mentioned on gut health pages, and when it is, it is often wrong.
Yin-Shuo Chang and Yu-Chen Huang pooled 23 case control studies with a total of 1,513 people with rosacea and calculated mite infestation and mite density separately.
The odds ratio for a Demodex infestation was 9.04, with an interval from 4.83 to 16.93. Mite density was raised with a standardised mean difference of 1.62, in the redness dominant form with 2.69 and in the papulopustular form with 2.80. The authors stress the high heterogeneity and that no cause can be derived from case control data.
For you that means: the numerically largest association in rosacea is a mite that lives in the hair follicle and the sebaceous gland of your facial skin.
Chang YS, Huang YC. J Am Acad Dermatol. 2017;77(3):441-447.e6. PMID: 28711190 · DOI: 10.1016/j.jaad.2017.03.040 [Meta-analysis, k=23, n=1,513]Demodex is not a gut mite and not a gut bacterium. I read this mix up regularly on German pages. Demodex folliculorum and Demodex brevis are skin mites. They live in the face of almost all adults, usually completely unremarkably.
That is no small matter. Anyone who places Demodex in the gut shifts the strongest number of the whole field into the wrong organ and justifies a treatment with it that misses the finding.
Helicobacter pylori, the chapter with four answers
Hardly any germ is named more often in this context. And hardly any has such an inconsistent body of data.
Anne Jørgensen and colleagues analysed 14 studies with 928 people with rosacea and 1,527 controls.
The overall association was an odds ratio of 1.68 with an interval from 1.00 to 2.84 and a p value of 0.052, so just short of significant. Restricted to studies using the urea breath test it rose to 3.12. For the effect of an eradication treatment on rosacea, seven studies gave a relative risk of 1.28 with p equal to 0.069, likewise not significant.
For you that means: the title says associated, the numbers say narrowly missed. And the more precisely it is measured, the bigger the signal becomes. That is the same dispute about measurement methods as with the breath test in the gut.
Jørgensen AHR, Egeberg A, Gideonsson R et al. J Eur Acad Dermatol Venereol. 2017;31(12):2010-2015. PMID: 28543746 · DOI: 10.1111/jdv.14352 [Meta-analysis, k=14, n=2,455]Ying Gao and colleagues pooled 25 datasets from 23 studies, with 51,054 people with rosacea and 4,709,074 controls.
Pooled, the odds ratio was 1.51 with high heterogeneity. In studies using one test it was 1.72, with several tests 2.26. In population based studies that defined an infection only through prescription data for eradication medication it was 0.90, so nothing at all.
For you that means: those who test find something. Those who search prescription data find nothing. That is the most honest summary of this question currently available.
Gao Y, Yang XJ, Zhu Y, Yang M, Gu F. PLoS One. 2024;19(4):e0301703. PMID: 38574094 · DOI: 10.1371/journal.pone.0301703 [Meta-analysis, k=25, n=4,760,128]Added to this is the Danish register cohort with a hazard ratio of 1.04, so nothing, and the American cross sectional study in which people with rosacea even had Helicobacter less often than the general population. The German guideline sums this up in two words: discussed controversially.
A Helicobacter eradication is not decided because of the skin. It is decided because of the stomach and because of the stomach cancer risk. If an eradication has been recommended to you, the uncertain skin data are no reason to turn it down, and an antibiotic therapy that has been started is not stopped on your own. How this decision comes about otherwise is described in Helicobacter pylori, treat or not.
The triggers that actually appear in the guideline
Before you think of the gut in rosacea, it is worth a look at the list that affected people report themselves. The German guideline gives it with percentages.
| Trigger | Share | Trigger | Share |
|---|---|---|---|
| UV radiation | 81 percent | Alcohol | 52 percent |
| Emotional stress | 79 percent | Hot bathing | 51 percent |
| Hot weather | 75 percent | Very cold weather | 46 percent |
| Wind | 57 percent | Spicy food | 45 percent |
| Physical exertion | 56 percent | Cosmetics | 41 percent |
Does anything strike you? The strongest single trigger is sunlight, the second strongest is mental tension. Neither appears in any gut cleanse offer.
On diet the guideline is very precise, and I like quoting it because it says two things at once. With the recommendation strength should and 100 percent agreement in the consensus procedure it advises avoiding foods that lead to vessel widening, for example alcohol, spicy food as well as hot food and drinks. In the same breath it states: even though no special rosacea diet can be recommended, these factors should be avoided.
In addition it names foods with plenty of biogenic amines, such as red wine or cheese, as a possible aggravating factor. If you wonder why exactly these foods keep turning up, the explanation is in Histamine intolerance and DAO deficiency.
Coeliac disease, inflammatory bowel disease and one important mistake
The Danish register cohort found a raised risk of coeliac disease in rosacea, hazard ratio 1.46. That is an association from which something actually follows, namely a question in the history taking.
If a suspicion of coeliac disease is ever in the room for you, then do not eat gluten free beforehand. The diagnostic work-up requires a gluten containing diet. Without gluten, antibodies and tissue changes recede so far that the diagnosis can no longer be made. That is written exactly like this in the European ESPGHAN guideline on coeliac disease diagnosis.
The consequence is unpleasant: you then have a dietary change without a diagnosis, without a claim to follow up care and without clarity for your relatives, who also carry a raised risk. How the correct order runs is described in Recognising coeliac disease.
Yu Kyung Jun and colleagues pooled eight studies and calculated the association between rosacea and inflammatory bowel disease in both directions.
In people with inflammatory bowel disease rosacea was more common, pooled odds ratio 1.86, with Crohn disease 1.74 and with ulcerative colitis 2.00. Conversely, in rosacea the risk of a later occurring bowel disease was raised, incidence rate ratio 1.37, for Crohn disease 1.60 and for ulcerative colitis 1.26.
For you that means: both directions are raised. That fits poorly with a simple chain from gut to skin and well with a shared immune predisposition that shows itself at two boundary surfaces.
Jun YK, Yu DA, Han YM et al. Dermatol Ther (Heidelb). 2023;13(7):1465-1475. PMID: 37338720 · DOI: 10.1007/s13555-023-00964-6 [Meta-analysis, k=8]What that means in practice is unspectacular and still important. Anyone with rosacea and persistent bowel complaints should have the bowel complaints taken seriously and not brushed aside as a side issue. The route leads to diagnostics, not to a cleanse. More on this in Crohn disease and ulcerative colitis viewed integratively.
In rosacea the gut is a supporting player, not a lead actor.
Sun, tension, heat and a mite together explain more than any overgrowth. Anyone who treats only the belly treats the smaller part, and the one for which the treatment data are least robust.
And now you know why in rosacea I first ask about sun protection, sleep and triggers, before a breath test even comes up.
What a stool test shows in rosacea, and why little follows from it
At some point the question about the stool test comes up in almost every conversation. You send in a sample, get a chart back, and on it are bacterial names with bars.
For rosacea there are exactly two serious investigations of this kind. I will put them side by side, because together they say more than each does alone.
Yi-Ju Chen and colleagues sequenced the stool of 11 people with rosacea and 110 controls matched for age, sex and body weight.
Microbial diversity was lower and the community structure was different. Enriched were Rhabdochlamydia, Bifidobacterium and Ruminococcus, among others. Reduced were Lactobacillus, Megasphaera and Acidaminococcus.
For you that means: eleven people. That is a hypothesis, not a finding. This work only becomes interesting through the next one.
Chen YJ, Lee WH, Ho HJ, Tseng CH, Wu CY. J Formos Med Assoc. 2021;120(1 Pt 1):256-264. PMID: 32446756 · DOI: 10.1016/j.jfma.2020.04.034 [Cohort, n=121]Jae Hui Nam and colleagues sequenced the stool of 12 women with rosacea from a screening programme and compared it with 251 controls.
Reduced were Methanobrevibacter, Slackia and Desulfovibrio, among others. Increased were Acidaminococcus, Megasphaera and an unknown genus of the Lactobacillales.
For you that means: exactly the bacterial groups that were reduced in Taiwan were increased in Korea. Two small studies, two countries, the same genera, opposite directions.
Nam JH, Yun Y, Kim HS et al. Exp Dermatol. 2018;27(1):37-42. PMID: 28636759 · DOI: 10.1111/exd.13398 [Cohort, n=263]The same three bacterial groups, two opposing results
Lactobacillus, Megasphaera and Acidaminococcus are reduced in Chen. Acidaminococcus, Megasphaera and Lactobacillales are increased in Nam.
These two studies are rarely placed side by side. Yet it is the clearest available reason why, at present, nothing can be derived from a stool finding about what a gut flora in rosacea ought to look like.
And that is no reproach to the researchers. Eleven and twelve people from two completely different food cultures give exactly what one would expect: noise with structure.
That leaves the study type that has been marketed for a few years as proof of causality: Mendelian randomisation. It uses genetic variants as a natural random allocation.
Jiaqi Li and colleagues carried out a two sample Mendelian randomisation, with gut flora data from the largest available genome wide association study and rosacea data from the Finnish FinnGen biobank, using 2,078 genetic instruments in total.
Two groups appeared protective, the phylum Actinobacteria and the genus Butyrivibrio, plus 14 further taxa with effects. The results section then states: not a single result withstood correction for multiple testing. All of them were only nominally significant.
For you that means: the title contains the word causal, the results section takes it back. When you see such studies quoted, it is worth looking at the section on the false discovery rate.
Li J, Yang F, Liu Y, Jiang X. Front Med (Lausanne). 2024;11:1322685. PMID: 38585146 · DOI: 10.3389/fmed.2024.1322685 [Mendelian Randomisation]What follows from this for the stool test in skin problems? By current standing, no course of action. A microbiome profile can be interesting, it can raise questions, and it can generate insight in studies. A skin treatment cannot be derived from it. What a stool test can do and what it cannot is described in Stool testing, PCR and dysbiosis diagnostics.
A finding from which no decision follows is not a finding. It is a number.
The useful question before any test is therefore: what would I do differently if the result comes out this way, and what if it comes out the other way? If both answers are the same, you do not need the test.
And now you know why I do not recommend a microbiome stool test for a purely skin related concern.
Acne, where the gut ends and metabolism begins
In acne the situation is different from rosacea. Here there is a very well documented route from inside to outside. It just does not run through the gut flora.
Blemished skin, causes in the gut or in metabolism
The sebaceous gland is an organ that listens to hormones. Two signals can turn it up: androgens and the insulin like growth factor IGF-1. When a lot of insulin is on the move, IGF-1 can rise, and at the same time the binding proteins that otherwise bind it can fall. More free IGF-1 can mean more sebum, stronger keratinisation and more food for the bacteria in the follicle.
That is not a theory out of nowhere. It has been measured in three places.
Robyn Smith and an Australian team randomised 43 young men with acne to a diet with a low glycaemic load or a control diet with carbohydrate dense foods. The skin was assessed blinded, so the assessors did not know who was in which group.
After 12 weeks the total lesions fell by 23.5 in the intervention group compared with 12.0 in the control group, p equal to 0.03. Insulin sensitivity improved, p equal to 0.026. At the same time the participants lost 2.9 kilograms, while the control group gained slightly.
For you that means: the effect is real and cleanly assessed. The authors write themselves, though, that weight loss and dietary change cannot be separated from one another in this design.
Smith RN, Mann NJ, Braue A, Mäkeläinen H, Varigos GA. Am J Clin Nutr. 2007;86(1):107-115. PMID: 17616769 · DOI: 10.1093/ajcn/86.1.107 [RCT, n=43]Hyuck Hoon Kwon and colleagues randomised 32 people in Korea with mild to moderate acne over 10 weeks to a diet with a low glycaemic load or a control diet and additionally took skin samples.
Inflammatory and non inflammatory skin lesions declined. In the tissue analysis they found smaller sebaceous glands, fewer signs of inflammation and a lower expression of SREBP-1 and interleukin-8.
For you that means: the route runs through the sebaceous gland and its control, not through a detox. Small group, short duration, but a rare look at the level underneath.
Kwon HH, Yoon JY, Hong JS et al. Acta Derm Venereol. 2012;92(3):241-246. PMID: 22678562 · DOI: 10.2340/00015555-1346 [RCT, n=32]Jennifer Burris and colleagues randomised 66 adults with moderate to severe acne to two weeks with a low glycaemic index or their usual diet. The target measures were blood values, not the skin.
IGF-1 fell in the intervention group from 267.3 to 244.5 nanograms per millilitre, p equal to 0.049. Glucose, insulin, IGFBP-3 and insulin resistance did not differ between the groups, and body composition stayed unchanged.
For you that means: two weeks are enough to lower IGF-1 measurably, and without weight loss. Whether that is enough to change the skin is something this study explicitly does not say.
Burris J, Shikany JM, Rietkerk W, Woolf K. J Acad Nutr Diet. 2018;118(10):1874-1885. PMID: 29691143 · DOI: 10.1016/j.jand.2018.02.009 [RCT, n=66]And then there is a natural experiment that has stayed in my mind for years.
Dan Ben-Amitai and Zvi Laron observed people with Laron syndrome, a congenital insensitivity to growth hormone. In them IGF-1 is permanently very low.
Untreated, hardly any acne was observed in these people during puberty. Under treatment with IGF-1, acne lesions appeared.
For you that means: this is the most compelling pointer to IGF-1 as a driving factor that exists in humans. Very small numbers, a rare condition, no control group. The direction is striking, a proof it is not.
Ben-Amitai D, Laron Z. J Eur Acad Dermatol Venereol. 2011;25(8):950-954. PMID: 21054577 · DOI: 10.1111/j.1468-3083.2010.03896.x [Case Series]The chain that is best studied in acne
- A meal with a high glycaemic load can drive blood sugar up quickly.
- Insulin rises, and with it free IGF-1 can rise, because the binding proteins can fall.
- IGF-1 and androgens can turn up the sebaceous gland, measurable at SREBP-1.
- More sebum and stronger keratinisation can block the follicle outlet.
- In the blocked follicle inflammation can arise, visible as a pustule.
What has been measured are single links of this chain, not the chain as a whole. Burris, for example, found only IGF-1 changed, while insulin and IGFBP-3 did not differ between the groups. What is striking nonetheless: this chain manages without gut flora. That is no criticism of the gut-skin axis, it is a sorting. In acne the best studied route runs through metabolism.
Milk, and why yoghurt drops out
A meta-analysis of observational studies by Mohadeseh Aghasi and colleagues compared the highest with the lowest intake category: dairy overall odds ratio 2.61, milk in total 1.48, low fat milk 1.25, skimmed milk 1.82. For yoghurt and cheese no significant association was found.
What stands out is that skimmed milk sits higher at 1.82 than milk overall at 1.48 and that fermented products drop out. A separate value for whole milk does not appear in this work, so the comparison has to be read cautiously. And the top value for dairy overall has a very wide confidence interval of 1.20 to 5.67, so it could be considerably smaller than the figure 2.61 makes it look. The pattern still fits the insulin explanation. What that means in practice and how robust observational data on milk are overall is described in Dairy products, healthy or not.
On blood sugar itself I keep it short here, because there is a separate article for it. What matters is not the individual sugar content but how fast and how high blood sugar rises after a meal and how often that happens in a day. Everything practical about it is in Avoiding blood sugar spikes. And if your skin changes with your cycle or is concentrated on the chin and jaw, the hormonal side is worth a look in Hormonal acne from within.
And how much of that is gut?
Honest answer: so far little, and the little there is is new.
Agata Lesiak and a Polish team took paired samples: skin swabs from the face and stool samples from 17 people with moderate to severe acne and 14 healthy controls.
Diversity in the gut was clearly lower in acne, across all indices with p less than 0.001, and the community structure differed as well. On the skin, diversity was reduced as well, but the composition differed considerably less there than in the gut.
For you that means: the clearer difference lay in the belly, but both were altered. That is remarkable and it remains a pilot study with 31 people in total, without any statement about cause and effect and without recording diet as a possible shared driver.
Lesiak A, Krawczyk A, Piasta J et al. Front Cell Infect Microbiol. 2026;16:1904271. PMID: 42625577 · DOI: 10.3389/fcimb.2026.1904271 [Cohort, n=31]Jeng-Wei Tjiu and Chia-Fang Lu searched systematically up to November 2025 for double blind randomised studies lasting at least four weeks. They found three, with 231 people in total.
Pooled, the standardised mean difference was minus 0.57 in favour of the probiotics for inflammatory lesions, with high heterogeneity. The 95 percent prediction interval ran from minus 1.25 to plus 0.11 and therefore includes zero. Tolerability was good in the short term across the three studies, and no serious adverse events were reported. That does not mean probiotics are harmless for everyone. The Cochrane review on eczema states that a small risk of adverse effects exists. In premature infants, in seriously ill or immunocompromised people and with an indwelling central venous catheter, live bacteria can in rare cases cause an infection themselves. For these groups every administration belongs in medical hands, and that applies to your child just as much.
For you that means: the point estimate looks decent, the prediction interval does not. Translated, it means the next study could just as well find no difference at all. Which preparation forms exist and how they differ is described in Probiotics, spore form or capsule.
Tjiu JW, Lu CF. Medicina (Kaunas). 2025;61(12):2152. PMID: 41470154 · DOI: 10.3390/medicina61122152 [Meta-analysis, k=3, n=231]Approaching acne from within does not mean treating the gut. It means calming metabolism down.
That is the good news in this section. The lever with the best data is not a preparation, it is the composition of your meals. And that one is free.
And now you know why with blemished skin I first ask about breakfast and not about your bowel movement.
Atopic dermatitis, where prevention and treatment part ways
With atopic eczema there is one sentence that I consider the most useful in this whole article. It goes: preventing and treating are two different questions, and they have different answers.
It all started in Finland in 2001.
Marko Kalliomäki and colleagues gave pregnant women Lactobacillus GG or placebo when at least one first degree relative in the family had atopic eczema, hay fever or asthma, and afterwards gave it to the infants for six months.
By the age of two, atopic eczema had been diagnosed in 46 of 132 children. In the probiotic group there were 15 of 64, under placebo 31 of 68. The relative risk was 0.51, the number needed to treat 4.5.
For you that means: a halving, in a high risk group with a high event rate. Numbers like these are rarely reproduced in other populations and with other bacterial strains.
Kalliomäki M, Salminen S, Arvilommi H et al. Lancet. 2001;357(9262):1076-1079. PMID: 11297958 · DOI: 10.1016/S0140-6736(00)04259-8 [RCT, n=132]And that is exactly what happened. The halving turned into a considerably smaller effect in the pooled analyses, but one that stayed stable.
Claudio Pelucchi and colleagues pooled 18 publications from 14 studies on giving probiotics in pregnancy or infancy.
The relative risk for atopic eczema was 0.79, for IgE associated eczema 0.80. The studies were homogeneous among themselves, and no indications of publication bias were found. It made no difference whether the mother, the child or both were treated.
For you that means: a decline of about one fifth. Real, but far from the halving of the Finnish study.
Pelucchi C, Chatenoud L, Turati F et al. Epidemiology. 2012;23(3):402-414. PMID: 22441545 · DOI: 10.1097/EDE.0b013e31824d5da2 [Meta-analysis, k=14]A second pooled analysis across 16 studies and 2,797 children arrived at a relative risk of 0.74 and named as its most important limitation that the studies defined eczema very differently. And an updated analysis across 21 studies found the effect above all with combination preparations, with intake by the mother and only up to about the age of two.
The most important sentence of this third analysis is a negative one: for asthma, hay fever, wheezing, allergic diseases overall and sensitisation, no significant effect was found.
The World Allergy Organization and McMaster University developed a guideline on this using GRADE methodology.
It states that the available evidence does not show that probiotics lower the risk of developing an allergy. Taking all endpoints into account, the panel nevertheless saw a likely net benefit that comes primarily from eczema prevention. Three suggestions follow from this: for pregnant women at high risk of an allergic child, for breastfeeding women with infants at high risk and for infants at high risk. All three are conditional, and the panel itself rates the certainty of the evidence as very low.
For you that means: this is the exact wording. Not probiotics prevent allergies, but a weak recommendation, only for eczema, only at raised risk, certainty of evidence by the panel's own assessment very low. And live bacteria are not harmless for everyone. In premature infants, in seriously ill or immunocompromised people and with an indwelling central venous catheter they can in rare cases cause an infection themselves. Giving them to a newborn or to a sick child therefore belongs in medical hands.
Fiocchi A, Pawankar R, Cuello-Garcia C et al. World Allergy Organ J. 2015;8(1):4. PMID: 25628773 · DOI: 10.1186/s40413-015-0055-2 [Guideline]The same group also looked at prebiotics, meaning the fibres that feed bacteria. It suggests them for infants who are not exclusively breastfed and advises against them in exclusively breastfed infants, both conditional and with very low certainty of evidence. On prebiotics in pregnancy or breastfeeding there was not a single study, which is why the panel deliberately gave no recommendation on that.
This one sentence says a lot about the ground on which prebiotics for the complexion are marketed in this country. What these substances actually do in the gut is described in Prebiotics and resistant starch.
And now the treatment
Up to here it has been about children who do not yet have eczema. The more common question is a different one: you already have atopic dermatitis. Do probiotics do anything?
Areti Makrgeorgou and colleagues analysed 39 randomised studies with 2,599 participants for Cochrane, from infancy to 55 years of age, with treatment durations from four weeks to six months.
For symptoms rated by the participants themselves or by parents, the difference was minus 0.44 points on a scale from 0 to 20, so no documented difference. For quality of life likewise no difference. Rated by investigators, there was a SCORAD decline of 3.91 points, while the clinically meaningful minimal difference is estimated at 8.7 points. A sequential analysis showed that the required sample size has already been exceeded.
For you that means: a statistically measurable effect below the threshold at which people notice it at all. And further studies with the same strains are unlikely to change that.
Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ et al. Cochrane Database Syst Rev. 2018;11(11):CD006135. PMID: 30480774 · DOI: 10.1002/14651858.CD006135.pub3 [Meta-analysis, k=39, n=2,599]Why the German guideline says no so clearly
The German S3 guideline on atopic dermatitis formulates a strong negative recommendation, consensus based and with 100 percent agreement: for treatment, general dietary measures such as supplements or a blanket avoidance of certain foods such as cow milk or gluten should not be used. The same applies to vitamins.
That sounds harsh. The reason behind it is not dogma, though, but safety, and I find it convincing.
One note belongs here, because gluten comes up. If a suspicion of coeliac disease is ever in the room for you or your child, then the diagnostic work-up belongs before the avoidance. A gluten free diet that begins beforehand can make the diagnosis impossible, because antibodies and mucosal findings recede under avoidance.
Blanket elimination diets in children come at a price
When milk, wheat, egg and nuts are cut preventively in a child with eczema, without an allergy having been confirmed, the most important protein, calcium and energy sources fall away with them. Malnutrition and growth disorders are documented as a result.
Added to this is a second, less well known point: a child who avoids a food for a long time can react more sensitively to it when it comes into contact with it again later. That is why the guideline relies on individual allergy diagnostics and on elimination diets only in confirmed, clinically relevant food allergy.
That is a safety argument, not a distrust of nutrition. And it applies far more strongly to children than to adults.
Hand eczema and dyshidrotic eczema, the little blisters on the palms and the sides of the fingers, are often assumed to come particularly clearly from the gut. Robust intervention studies on this do not exist. What applies to atopic eczema applies here all the more: first the dermatological classification, then everything else.
The hygiene hypothesis, cleanly classified
Michelle Stein and a large team compared 60 children from two US farming communities with very similar genetics and way of life but opposite farming practice: traditional among the Amish, industrial among the Hutterites.
Asthma was four times less common in the Amish children, allergic sensitisation six times less common. The endotoxin content in house dust was 6.8 times higher. In the accompanying mouse experiment, Amish house dust suppressed airway hypersensitivity while Hutterite dust did not, and in mice lacking certain signalling proteins the protection disappeared.
For you that means: the cleanest support for the biodiversity hypothesis there is. It concerns the airways and sensitisation, though, not the skin directly. And the mouse part is a mouse part.
Stein MM, Hrusch CL, Gozdz J et al. N Engl J Med. 2016;375(5):411-421. PMID: 27518660 · DOI: 10.1056/NEJMoa1508749 [Cohort, n=60]What makes this finding interesting for the skin nonetheless is the barrier parallel. In atopic eczema the skin barrier is disturbed, often through a predisposition in the filaggrin gene. The skin loses water, irritants and allergens get in more easily, and the immune system gets to know them through the skin instead of through the gut. This order is considered one explanation for why food allergies are more common in children with eczema. The parallel to the gut barrier is obvious, and it is exactly that: a parallel. More on this in Leaky gut and zonulin.
In eczema the gut is more a window than a door.
In prevention, within a narrow time window, at raised risk, something can be influenced through the gut. With an existing eczema this window is largely closed by current data. That is uncomfortable and it saves you money and time.
And now you know why with an existing atopic dermatitis I do not start with probiotics but with the barrier and the dermatological treatment.
Psoriasis, the finding with the clearest practical consequence
In psoriasis the data look different. Here there is no cleanse story, but there is a number from which something follows.
Yun Fu, Cheng-Han Lee and Ching-Chi Chi searched MEDLINE, Embase and Cochrane Central and pooled five case control or cross sectional studies and four cohort studies with a total of 7,794,087 participants.
Psoriasis and Crohn disease were associated with an odds ratio of 1.70, psoriasis and ulcerative colitis with 1.75. For a newly occurring Crohn disease in existing psoriasis the relative risk was 2.53, and for ulcerative colitis 1.71.
For you that means: the authors recommend something very concrete from this. In psoriasis with bowel complaints, a gastroenterological work-up should be considered.
Fu Y, Lee CH, Chi CC. JAMA Dermatol. 2018;154(12):1417-1423. PMID: 30422277 · DOI: 10.1001/jamadermatol.2018.3631 [Meta-analysis, k=9, n=7,794,087]That is the only sentence in this whole article from which a clear action follows. And it leads not to a preparation but to an examination.
Why this fits together so well is understandable immunologically. Psoriasis and inflammatory bowel diseases share risk genes, they share signalling pathways in the immune system, and they are treated in part with the same antibody medications. Two diseases at two boundary surfaces, with a shared immunological ground. That is something other than a chain from gut to skin.
If you have psoriasis and persistent bowel complaints, that belongs in a work-up. Not because of a cleanse, but because of the possibility of a so far unrecognised inflammatory bowel disease. What is examined then and what integrative support can contribute is described in Crohn disease and ulcerative colitis integratively.
Not every connection between gut and skin leads to a treatment. Some lead to an examination, and that is worth more.
Finding an unrecognised inflammatory bowel disease earlier changes the course of a disease. A supplement whose effect lies below the threshold of perception mainly changes your bank balance.
And now you know why this number is the practically most useful one in the whole field.
What follows from this in practice, and where the evidence ends
Now everything is on the table. Time to sort it.
Which skin condition goes with which gut finding, and how well documented that is
Five bars mean several concordant randomised studies or meta-analyses with a clear effect. One bar means single findings that contradict each other or come from very small groups. The rating is my own classification of the quoted sources, not an official system.
What stands out in this overview: the strongest bars sit with associations from which diagnostics follow, and the weakest with everything that is sold as a product.
When a gut work-up in skin problems may be worth it
Situations in which I look closely
- Rosacea with papules and pustules plus concurrent abdominal complaints. Here the question about small intestinal bacterial overgrowth is covered by the data, and as an examination, not as an assumption.
- Psoriasis with persistent bowel symptoms. A gastroenterological work-up, for the reason named above.
- Skin complaints with coeliac disease in the family or with matching accompanying signs such as iron deficiency, bloating or weight loss. Keep eating gluten until the diagnostic work-up is done.
- Any skin condition together with a gut red flag from the box above. Then the work-up comes first, always.
- Recurring complaints after several courses of antibiotics or after a gastrointestinal infection with a permanently changed stool afterwards. What may make sense then is described in The gut after antibiotics.
And when I do not
- A skin condition without any abdominal symptoms and without red flags. Then the probability that a gut examination changes anything is low, and the costs are certain.
- A microbiome stool test just to see what it looks like. No skin treatment currently follows from the result.
- A gut cleanse before the skin has even been classified dermatologically. Rosacea, perioral dermatitis, seborrhoeic eczema and acne look more alike than you would think, and they are treated differently. A persistent redness across the cheeks and the bridge of the nose can also be something other than rosacea, for example an autoimmune disease such as lupus erythematosus.
The order I stand for across the whole cluster
Before anything else happens, I ask whether there is enough stomach acid up top, because it stands at the beginning of the digestive chain and is overlooked most often. Why that is so is described in Low stomach acid and betaine HCl. That is a question, not a recommendation for a self experiment. Acidifying preparations can do harm with a gastric ulcer, with gastritis and alongside anti inflammatory painkillers, so this question belongs in an examination and not in a trial run. And it is explicitly not an invitation to tinker with ongoing medication. Anyone taking an acid blocker, a laxative, an antibiotic or an immunosuppressive medication does not stop it on their own, does not reduce it and does not switch it. Every change to it belongs in a medical conversation and with medical supervision, because an abrupt stop can cause complaints of its own.
After that comes what actually feeds the microbiome, meaning plant variety and fibre. Why the often quoted number 30 is more marketing than physiology is described in Fibre myths. The overall concept with phases and diagnostics is in Gut reset, the whole gut approach.
No gut measure replaces a dermatological diagnosis or a recommended skin treatment. If you already receive a therapy, whether as a cream, a tablet or an antibody, then it is not changed, reduced or stopped on your own because you are trying something in the gut. Every adjustment belongs in a medical conversation and with medical supervision.
The question is not whether you should do something for your gut. It is what you are doing it for.
Plant variety, calm blood sugar, enough sleep and less constant tension make sense for many reasons. If your skin benefits from that, it is a welcome side effect. If you do it exclusively for the skin, disappointment becomes more likely than success.
And now you know why my answer to the question about a gut cleanse for the complexion almost always begins with a question back.
Why gut cleanse programmes for the skin often promise more than the data hold
I write this section reluctantly, because it turns against something that is actually close to me. I work a lot with the gut. I consider it underrated. And still this belongs here, because otherwise nobody says it.
When a gut cleanse promises you a better complexion, four things stand between that promise and the data.
First: the studies are small
Look at the sample sizes that appear in this article. Eleven people in Chen. Twelve in Nam. Seventeen against fourteen in Lesiak. Twenty seven in Nelson. Two hundred and thirty one spread across three probiotic studies in acne.
These are numbers from which research arises. They are not numbers from which treatment recommendations arise. For comparison: the Danish register cohort covered 49,475 people with rosacea, the psoriasis meta-analysis almost eight million participants. When the same question is answered once with eleven and once with fifty thousand people, that is not a tie.
Second: the findings contradict each other
The clearest case stands further up. Lactobacillus, Megasphaera and Acidaminococcus are reduced in Taiwan and increased in Korea, in the same condition.
When two investigations point in opposite directions for the same bacteria, then a statement such as your gut flora looks like this and that in this skin condition simply cannot hold. At least one of the two investigations must be wrong, and probably both are too small to hit anything.
Third: association is not cause
Rosacea and inflammatory bowel disease are associated in both directions. People with bowel disease more often have rosacea, and people with rosacea more often develop a bowel disease.
A chain from gut to skin cannot explain that. A shared immune predisposition that shows itself at both boundary surfaces explains it very well. The difference is practical: in the first case you treat the gut and the skin follows. In the second case you treat both organs where they are ill.
Fourth: skin conditions fluctuate on their own
This is the most underrated point, and it decides how much testimonials are worth.
Rosacea runs in flares. Acne changes with season, cycle, sleep and tension. Atopic dermatitis gets better in summer for many people and worse in winter. Anyone who starts a cleanse in a bad phase experiences an improvement with high probability. In many cases that improvement would have come without the cleanse as well.
Exactly for this reason the unblinded skin assessment in the Parodi study is a real problem, even though I consider this study the strongest in the field. And exactly for this reason the blinded assessment in Smith is so valuable.
Three questions that decide almost everything
Did the person doing the rating know who had been treated? If so, the rating is vulnerable, and in both directions. That is not dishonesty, that is perception.
Was there a group that received nothing or something inactive? Without a comparison group you measure the natural course along with it.
How many people took part? Below thirty people a single good course can tip the result.
What remains nonetheless
Now comes the part that matters to me, because otherwise this section sounds like a refusal. It is not one.
What remains of the gut-skin axis, and that is not little
- A diet that keeps blood sugar calm has documented effects in acne. Two randomised studies, one of them with blinded assessment, plus the measured intermediate step through IGF-1.
- In papulopustular rosacea with abdominal complaints the question about the small intestine is justified. It leads to a test and, if appropriate, to a medically supervised treatment.
- A genuine bowel disease belongs in treatment. Coeliac disease, Crohn disease, ulcerative colitis. These associations are well documented, and they lead to diagnostics.
- Fibre and plant variety make sense for many reasons. Even when the effect on your complexion remains unproven.
- In prevention in infants at raised risk there is a real, small effect. Limited in time and with honestly named uncertainty.
That is less than what is advertised. And clearly more than nothing.
On gut cleansing, enemas and colon hydrotherapy I deliberately say nothing here, neither good nor bad. That belongs in a text of its own, and that text is Gut cleansing, enema and colon hydrotherapy.
In skin conditions the gut is a serious supporting player. In most people it is not the cause.
That is why I do not treat skin through the gut. I look for a gut finding when there is a reason for it, and then I take it seriously. Where I see no reason, I say so. Where no efficacy data exist for an offer, money and time can be tied up in a place where a better documented treatment might achieve more. That is not a reproach against individual providers, it is a statement about the data.
- The key study is not replicated. Parodi 2008 comes from a single centre, the skin assessment was not blinded, the randomisation groups were small. A large multicentre study on this is still missing today, and the German guideline says so explicitly.
- The largest body of data does not find the association. Egeberg 2017 arrives at a hazard ratio of 0.71 for small intestinal bacterial overgrowth, with an interval from 0.18 to 1.86. My reading that register data can hardly capture this finding is plausible and remains a reading.
- The microbiome studies are too small for conclusions. Eleven and twelve affected people with opposing results allow no statement about the gut flora in rosacea.
- The two mechanism studies are mouse experiments. Furusawa 2013 and Zelante 2013 are excellent works and they say nothing about human skin.
- In acne the gut share is a hypothesis. Lesiak 2026 is a pilot study with 31 people in total and does not record diet, although it could be a shared driver.
- The milk data are observational data, often from retrospective questionnaires and therefore vulnerable to recall bias.
- The probiotic meta-analysis in acne rests on three studies. The prediction interval includes zero, and the certainty of the evidence is given as low to moderate.
- The eczema prevention applies narrowly only. It concerns children at raised risk, shows itself above all up to about two years and reveals no effect on asthma, hay fever or sensitisation.
- The Amish and Hutterite study concerns airways, not skin, and contains a mouse component. It stands here as a framing finding on biodiversity.
- On acne therapy I quote no guideline recommendation. Of the European work only the methods report was available to me for checking, and the German S2k guideline on acne was not retrievable in full text at the time of research.
- What deliberately does not appear here. No dosing recommendation, no cleanse plan, no sources of supply and no advice to change, reduce or stop existing skin or stomach medication. From no section does it follow that a recommended work-up, endoscopy or eradication should be skipped. What I describe from my consultations is marked as observation and is not a study result.
Common questions about gut and skin
These are the questions I am asked most often on this topic. The answers deliberately carry numbers, so that you can use them further.
Can the gut really be to blame for my skin?
In a subgroup of people, several findings suggest that the gut has a say. Blame is still the wrong word. What is documented are associations, not causal chains. The clearest finding is in rosacea, where small intestinal bacterial overgrowth was found in 52 of 113 affected people and in 3 of 60 controls. In acne, the documented route runs through insulin and IGF-1 and not through the gut flora. In most people with blemished skin, no gut finding turns up that would carry a treatment.
How strong is the link between rosacea and small intestinal bacterial overgrowth really?
In the Italian work by Parodi 2008 the breath test was positive in 52 of 113 people with rosacea and in 3 of 60 matched controls, that is 46 against 5 percent. The German S2k guideline on rosacea gives a range of 46 to 51 percent against 5 to 23 percent and lists the overgrowth explicitly as a trigger factor. In the same passage stands the sentence that large randomised multicentre studies validating these observations are still missing. Both belong together.
I read that SIBO is thirteen times more common in rosacea. Is that true?
That number cannot be traced to any primary source. The original values are 46 percent against 5 percent in Parodi, which corresponds to a frequency ratio of about nine. The German guideline gives 46 to 51 percent against 5 to 23 percent. In the Danish register cohort with 49,475 affected people no signal for the overgrowth was detectable at all. When you meet a number that appears in no study, that is a good moment to ask for the source.
Does a gut restoration programme do anything for rosacea, and what about the testimonials?
Testimonials carry particularly little weight in this field, and there are two reasons for that. Rosacea fluctuates on its own in flares, so an improvement during a programme might well have come without it. And in the most important study two dermatologists rated the skin without being blinded to the therapy. What has been studied most closely is something other than a cleanse: the targeted treatment of a confirmed overgrowth after a positive breath test, with medical supervision and with a prescription only antibiotic outside its licence. The data for this come from a single study with unblinded skin assessment. The German guideline states explicitly that large randomised multicentre studies confirming this are still missing.
What does SIBO have to do with the skin?
SIBO stands for bacterial overgrowth of the small intestine. It can cause flatulence, abdominal pain and changes in bowel movement, and in several investigations it occurs more often in rosacea than in controls. Whether it influences the skin or whether both grow on shared ground is open. How the breath test works and how treatment is done is covered in detail in the separate article on bacterial overgrowth of the small intestine.
Should I have a microbiome stool test done for skin problems?
At present no course of action follows from it. Two microbiome studies in rosacea point in opposite directions for the same bacterial genera. In Chen 2021 Lactobacillus, Megasphaera and Acidaminococcus were reduced, in Nam 2018 Acidaminococcus, Megasphaera and Lactobacillales were increased. Eleven and twelve affected people, two countries, opposing results. Anyone who derives a skin concept from such a finding goes beyond the data.
Is Helicobacter pylori an issue in rosacea?
The data are contradictory. Jørgensen 2017 found an odds ratio of 1.68 across 14 studies with p equal to 0.052, so just short of significant, while in the subgroup with breath testing it was 3.12. Gao 2024 found 1.51 pooled, but 0.90 in register studies based on prescription data. Egeberg 2017 found nothing in the Danish cohort. The decisive point is this: an eradication is not decided because of the skin, it is decided because of the stomach and the cancer risk. If an eradication has been recommended to you, skin questions are no reason to turn it down.
Does acne come from the gut or from sugar?
What is documented is the metabolic route. In two randomised studies the number of skin lesions fell further under a diet with a low glycaemic load than in the comparison group. In Smith 2007 it was 23.5 lesions fewer against 12.0 in the control group. So both groups improved. Participants in the intervention group also lost nearly three kilograms at the same time, which is why the authors themselves write that weight loss and dietary change cannot be separated here. Burris 2018 showed that IGF-1 can fall measurably within two weeks. In people with Laron syndrome, who largely lack IGF-1, hardly any acne was observed during puberty, and under treatment with IGF-1 acne lesions then appeared. That is an observation in very few people with a rare condition, without a control group. The gut share, by contrast, is so far a hypothesis, supported by a pilot study with 17 against 14 people.
Do I have to drop milk so my skin gets better?
The data do not support a ban. In the meta-analysis by Aghasi 2019 across observational studies the odds ratio was 2.61 for dairy overall and 1.48 for milk, 1.82 for skimmed milk and 1.25 for low fat milk. For yoghurt and cheese no signal was found. It is striking that skimmed milk sits higher at 1.82 than milk overall at 1.48 and that fermented products drop out. A separate value for whole milk does not appear in this work, so the comparison has to be read cautiously. The top value of 2.61 also has a very wide confidence interval of 1.20 to 5.67. The pattern still fits the insulin explanation. A time limited trial is quite defensible, a permanent avoidance without a noticeable difference is not.
Do probiotics help against acne?
Tjiu 2025 found only three double blind randomised studies with 231 people in total. Pooled, the standardised mean difference was minus 0.57 in favour of the probiotics for inflammatory lesions. The more important number is the prediction interval from minus 1.25 to plus 0.11. Translated, that means the next study could just as well find no difference at all. For one of the most heavily marketed supplements that is a very thin foundation.
Do probiotics help in atopic dermatitis?
Here prevention and treatment separate cleanly. For prevention in raised risk the meta-analyses show a relative risk of 0.79 and 0.74, so about a fifth to a quarter fewer cases of eczema. For treating an existing eczema the Cochrane review across 39 studies and 2,599 people found no difference in self reported symptoms. Rated by investigators, the result was minus 3.91 SCORAD points, while the clinically meaningful minimal difference is estimated at 8.7 points.
Should I take probiotics in pregnancy so my child does not get eczema?
The guideline of the World Allergy Organization puts this very carefully. It states that the available evidence does not show a reduction in overall allergy risk, but it sees a likely net benefit that comes primarily from eczema prevention. Three conditional suggestions follow from this, for pregnant women, breastfeeding women and infants at raised risk, and the panel itself rates the certainty of the evidence as very low. This decision belongs in a conversation with the doctor looking after you.
I have psoriasis and abdominal complaints. Do I need to do something?
This is the clearest action sentence in this article. In the meta-analysis by Fu 2018 across 7.79 million participants the odds ratio was 1.70 for Crohn disease and 1.75 for ulcerative colitis, and the risk of newly occurring inflammatory bowel disease was clearly raised. The authors recommend considering a gastroenterological work-up in psoriasis with bowel complaints. That leads to diagnostics, not to a cleanse.
How long does it take for the skin to change when I change something in the gut?
The data do not provide a fixed timeframe. The studies with skin endpoints ran 10 to 12 weeks, and in Parodi the eradication was checked one month after the end of therapy. If you change something, a window of about three months is a realistic frame for observation. And because rosacea and acne fluctuate on their own, a single good month is not yet proof. Photos in the same light are more honest than memory.
Where gut and skin dock onto the rest of the body
Both organs hang on the same foundations. On what you eat, on your sleep, on your nervous system and on what your immune system currently considers dangerous.
Hormonal acne
When the skin changes with the cycle and is concentrated at the jaw
Dairy in context
What the study data on milk actually hold, beyond the camps
Blood sugar spikes
The lever with the best data in blemished skin
Inflammatory foods
Why the usual lists often miss the essential point
Paleo and AIP
What elimination concepts can do and where their limits lie
Histamine and DAO
Red wine, cheese and the question of biogenic amines
Sleep and microbiome
The underrated pacemaker for both boundary surfaces
Gut-brain axis
Why tension is the second strongest rosacea trigger
Scientific sources
- Clanner-Engelshofen BM, Bernhard D, Dargatz S, Flaig MJ, Gieler U, Kinberger M et al. S2k-Leitlinie: Rosazea. J Dtsch Dermatol Ges. 2022;20(8):1147-1167. AWMF register no. 013-065, as of 28 January 2022, valid until 31 December 2026. PMID: 35971589 · DOI: 10.1111/ddg.14849_g [Guideline]
- Werfel T, Heratizadeh A, Aberer W et al. S3 Guideline Atopic dermatitis: Part 1. General aspects, topical and non-drug therapies, special patient groups. J Dtsch Dermatol Ges. 2024;22(1):137-153. AWMF register no. 013-027. PMID: 38171719 · DOI: 10.1111/ddg.15230 [Guideline]
- Fiocchi A, Pawankar R, Cuello-Garcia C, Ahn K, Al-Hammadi S, Agarwal A et al. World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. World Allergy Organ J. 2015;8(1):4. PMID: 25628773 · DOI: 10.1186/s40413-015-0055-2 [Guideline]
- Cuello-Garcia CA, Fiocchi A, Pawankar R, Yepes-Nunez JJ, Morgano GP, Zhang Y et al. World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Prebiotics. World Allergy Organ J. 2016;9:10. PMID: 26962387 · DOI: 10.1186/s40413-016-0102-7 [Guideline]
- Husby S, Koletzko S, Korponay-Szabo I, Kurppa K, Mearin ML, Ribes-Koninckx C et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. J Pediatr Gastroenterol Nutr. 2020;70(1):141-156. PMID: 31568151 · DOI: 10.1097/MPG.0000000000002497 [Guideline]
- Nast A, Dreno B, Bettoli V, Bukvic Mokos Z, Degitz K, Dressler C et al. Methods report on the development of the European evidence-based (S3) guideline for the treatment of acne, update 2016. J Eur Acad Dermatol Venereol. 2016;30(8):e1-e28. PMID: 27514933 · DOI: 10.1111/jdv.13783 [Guideline]
- Parodi A, Paolino S, Greco A, Drago F, Mansi C, Rebora A, Parodi A, Savarino V. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759-764. PMID: 18456568 · DOI: 10.1016/j.cgh.2008.02.054 [RCT, n=113]
- Agnoletti AF, De Col E, Parodi A, Schiavetti I, Savarino V, Rebora A, Paolino S, Cozzani E, Drago F. Etiopathogenesis of rosacea: a prospective study with a three-year follow-up. G Ital Dermatol Venereol. 2017;152(5):418-423. PMID: 26889725 · DOI: 10.23736/S0392-0488.16.05315-3 [Cohort, n=100]
- Nelson JM, Rizzo JM, Greene RK, Fahlstrom K, Troost JP, Helfrich YR, Nakamura M. Evaluation of Helicobacter pylori and Small Intestinal Bacterial Overgrowth in Subjects With Rosacea. Cureus. 2024;16(10):e72363. PMID: 39583431 · DOI: 10.7759/cureus.72363 [Cohort, n=27]
- Egeberg A, Weinstock LB, Thyssen EP, Gislason GH, Thyssen JP. Rosacea and gastrointestinal disorders: a population-based cohort study. Br J Dermatol. 2017;176(1):100-106. PMID: 27501017 · DOI: 10.1111/bjd.14930 [Cohort, n=4,361,688]
- Jun YK, Yu DA, Han YM, Lee SR, Koh SJ, Park H. The Relationship Between Rosacea and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Dermatol Ther (Heidelb). 2023;13(7):1465-1475. PMID: 37338720 · DOI: 10.1007/s13555-023-00964-6 [Meta-analysis, k=8]
- Jørgensen AHR, Egeberg A, Gideonsson R, Weinstock LB, Thyssen EP, Thyssen JP. Rosacea is associated with Helicobacter pylori: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(12):2010-2015. PMID: 28543746 · DOI: 10.1111/jdv.14352 [Meta-analysis, k=14, n=2,455]
- Gao Y, Yang XJ, Zhu Y, Yang M, Gu F. Association between rosacea and helicobacter pylori infection: A meta-analysis. PLoS One. 2024;19(4):e0301703. PMID: 38574094 · DOI: 10.1371/journal.pone.0301703 [Meta-analysis, k=25, n=4,760,128]
- Chang YS, Huang YC. Role of Demodex mite infestation in rosacea: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):441-447.e6. PMID: 28711190 · DOI: 10.1016/j.jaad.2017.03.040 [Meta-analysis, k=23, n=1,513]
- Chen YJ, Lee WH, Ho HJ, Tseng CH, Wu CY. An altered fecal microbial profiling in rosacea patients compared to matched controls. J Formos Med Assoc. 2021;120(1 Pt 1):256-264. PMID: 32446756 · DOI: 10.1016/j.jfma.2020.04.034 [Cohort, n=121]
- Nam JH, Yun Y, Kim HS, Kim HN, Jung HJ, Chang Y, Ryu S, Shin H, Kim HL, Kim WS. Rosacea and its association with enteral microbiota in Korean females. Exp Dermatol. 2018;27(1):37-42. PMID: 28636759 · DOI: 10.1111/exd.13398 [Cohort, n=263]
- Li J, Yang F, Liu Y, Jiang X. Causal relationship between gut microbiota and rosacea: a two-sample Mendelian randomization study. Front Med (Lausanne). 2024;11:1322685. PMID: 38585146 · DOI: 10.3389/fmed.2024.1322685 [Mendelian Randomisation]
- Wang FY, Chi CC. Rosacea, Germs, and Bowels: A Review on Gastrointestinal Comorbidities and Gut-Skin Axis of Rosacea. Adv Ther. 2021;38(3):1415-1424. PMID: 33507499 · DOI: 10.1007/s12325-021-01624-x [Mechanism Review]
- Searle T, Ali FR, Carolides S, Al-Niaimi F. Rosacea and the gastrointestinal system. Australas J Dermatol. 2020;61(4):307-311. PMID: 32761824 · DOI: 10.1111/ajd.13401 [Mechanism Review]
- Grafanaki K, Bakoli Sgourou D, Maniatis A, Pasmatzi E. The exposomal imprint on rosacea: More than skin deep. J Eur Acad Dermatol Venereol. 2026;40(3):387-403. PMID: 41081484 · DOI: 10.1111/jdv.70112 [Mechanism Review]
- Smith RN, Mann NJ, Braue A, Mäkeläinen H, Varigos GA. A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. Am J Clin Nutr. 2007;86(1):107-115. PMID: 17616769 · DOI: 10.1093/ajcn/86.1.107 [RCT, n=43]
- Kwon HH, Yoon JY, Hong JS, Jung JY, Park MS, Suh DH. Clinical and histological effect of a low glycaemic load diet in treatment of acne vulgaris in Korean patients: a randomized, controlled trial. Acta Derm Venereol. 2012;92(3):241-246. PMID: 22678562 · DOI: 10.2340/00015555-1346 [RCT, n=32]
- Burris J, Shikany JM, Rietkerk W, Woolf K. A Low Glycemic Index and Glycemic Load Diet Decreases Insulin-like Growth Factor-1 among Adults with Moderate and Severe Acne: A Short-Duration, 2-Week Randomized Controlled Trial. J Acad Nutr Diet. 2018;118(10):1874-1885. PMID: 29691143 · DOI: 10.1016/j.jand.2018.02.009 [RCT, n=66]
- Ben-Amitai D, Laron Z. Effect of insulin-like growth factor-1 deficiency or administration on the occurrence of acne. J Eur Acad Dermatol Venereol. 2011;25(8):950-954. PMID: 21054577 · DOI: 10.1111/j.1468-3083.2010.03896.x [Case Series]
- Aghasi M, Golzarand M, Shab-Bidar S, Aminianfar A, Omidian M, Taheri F. Dairy intake and acne development: A meta-analysis of observational studies. Clin Nutr. 2019;38(3):1067-1075. PMID: 29778512 · DOI: 10.1016/j.clnu.2018.04.015 [Meta-analysis]
- Lesiak A, Krawczyk A, Piasta J, Spalek J, Szajkowska J, Papros E, Krecisz B, Durnas B, Gosiewski T, Bucki R. Gut and skin dysbiosis in acne vulgaris: a comparative microbiome analysis. Front Cell Infect Microbiol. 2026;16:1904271. PMID: 42625577 · DOI: 10.3389/fcimb.2026.1904271 [Cohort, n=31]
- Tjiu JW, Lu CF. Oral Probiotics in Acne vulgaris: A Systematic Review and Meta-Analysis of Double-Blind Randomized Clinical Trials. Medicina (Kaunas). 2025;61(12):2152. PMID: 41470154 · DOI: 10.3390/medicina61122152 [Meta-analysis, k=3, n=231]
- Bowe WP, Logan AC. Acne vulgaris, probiotics and the gut-brain-skin axis: back to the future? Gut Pathog. 2011;3(1):1. PMID: 21281494 · DOI: 10.1186/1757-4749-3-1 [Mechanism Review]
- Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357(9262):1076-1079. PMID: 11297958 · DOI: 10.1016/S0140-6736(00)04259-8 [RCT, n=132]
- Pelucchi C, Chatenoud L, Turati F, Galeone C, Moja L, Bach JF, La Vecchia C. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012;23(3):402-414. PMID: 22441545 · DOI: 10.1097/EDE.0b013e31824d5da2 [Meta-analysis, k=14]
- Mansfield JA, Bergin SW, Cooper JR, Olsen CH. Comparative probiotic strain efficacy in the prevention of eczema in infants and children: a systematic review and meta-analysis. Mil Med. 2014;179(6):580-592. PMID: 24902123 · DOI: 10.7205/MILMED-D-13-00546 [Meta-analysis, k=16, n=2,797]
- Sun S, Chang G, Zhang L. The prevention effect of probiotics against eczema in children: an update systematic review and meta-analysis. J Dermatolog Treat. 2022;33(4):1844-1854. PMID: 34006167 · DOI: 10.1080/09546634.2021.1925077 [Meta-analysis, k=21]
- Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, Murrell DF, Tang MLK, Roberts A, Boyle RJ. Probiotics for treating eczema. Cochrane Database Syst Rev. 2018;11(11):CD006135. PMID: 30480774 · DOI: 10.1002/14651858.CD006135.pub3 [Meta-analysis, k=39, n=2,599]
- Stein MM, Hrusch CL, Gozdz J, Igartua C, Pivniouk V, Murray SE et al. Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med. 2016;375(5):411-421. PMID: 27518660 · DOI: 10.1056/NEJMoa1508749 [Cohort, n=60]
- Fu Y, Lee CH, Chi CC. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018;154(12):1417-1423. PMID: 30422277 · DOI: 10.1001/jamadermatol.2018.3631 [Meta-analysis, k=9, n=7,794,087]
- Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446-450. PMID: 24226770 · DOI: 10.1038/nature12721 [In vivo, mouse]
- Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39(2):372-385. PMID: 23973224 · DOI: 10.1016/j.immuni.2013.08.003 [In vivo, mouse]